TrialESMO open2022

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.

G Lo Russo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.